NANOVESICLES DERIVED FROM RHIZOBIUM SP. BACTERIA, AND USE THEREOF

WIPO Patent Application WO/2019/168328

A1

The present invention relates to vesicles derived from Rhizobium sp. bacteria, and a use thereof. The present inventors have experimentally ascertained that the vesicles in clinical samples from patients with stomach cancer, colorectal cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease and dementia are significantly reduced in comparison to those from normal people, and when the vesicles derived from the strains are administered, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited. Therefore, the vesicles derived from Rhizobium sp. bacteria, according to the present invention, can be effectively used for the purpose of developing a method for diagnosis of stomach cancer, colorectal cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia, and a composition for preventing, alleviating or treating the diseases.

KIM YOON-KEUN (KR)

PCT/KR2019/002342

September 06, 2019

February 27, 2019

Click for automatic bibliography generation  

MD HEALTHCARE INC (KR)

C12Q1/689; A23L33/135; A61K35/74; A61P35/00; A61P37/00; C12Q1/6851

KR20160073157A	2016-06-24
KR20110025068A	2011-03-09
KR20180018354A	2018-02-21
KR20180006303A	2018-01-17

YOON, HYUK ET AL.: "Comparisons of Gut Microbiota Among Healthy Control, Patients With Conventional Adenoma, Sessile Serrated Adenoma, and Colorectal Cancer", J. CANCER PREV., vol. 22, no. 2, June 2017 (2017-06-01), pages 108 - 114, XP055634725, ISSN: 2288-3649, DOI: 10.15430/JCP.2017.22.2.108
See also references of EP 3760743A4

LEE, Myoung-Jin (KR)

View/Download PDF      PDF Help

Previous Patent: NANOVESICLES DERIVED FROM MICROCOCCUS BACTERIA AND USE THEREOF

Next Patent: NANOVESICLES DERIVED FROM ACINETOBACTER BACTERIA AND USE THEREOF